Alzheimer’s disease and early-stage cognitive decline
Alzheon Inc. focuses on clinical research in Alzheimer’s disease among APOE4 carriers, particularly individuals with APOE4/4 and APOE3/4 genotypes who are in the early stage of disease. The research interest centers on patients aged 50 to 80 years with clinically diagnosed Alzheimer’s disease.
- APOE4-related Alzheimer’s disease
- Early symptomatic disease
- Genotype-defined patient populations
The sponsor’s clinical activity is concentrated in North America and involves collaboration across multiple research sites, with active work extending across two countries.
Biomarker-based assessment of Alzheimer’s pathology
Research interest includes plasma markers linked to core Alzheimer’s disease biology, with attention to p-tau181 as a measure of disease-related change. This reflects a therapeutic focus on tracking biological activity associated with neurodegeneration and amyloid-related pathology.
- Plasma biomarkers
- p-tau181
- Core AD pathology
The sponsor’s trial portfolio shows an emphasis on measurable molecular indicators relevant to progression in Alzheimer’s disease.
Neuroimaging and brain volume evaluation
Another area of interest is structural neuroimaging, including assessment of hippocampal volume on MRI. This aligns with research into brain regions affected early in Alzheimer’s disease and the monitoring of anatomical change over time.
- Hippocampal volume
- Volumetric MRI
- Structural brain changes
These imaging endpoints place focus on degeneration in memory-related brain structures relevant to cognitive impairment.
Oral therapeutic development in neurodegenerative disease
Alzheon Inc. is engaged in research on an oral treatment for Alzheimer’s disease, with therapeutic interest directed toward patients carrying the APOE4 genotype. The sponsor’s work is centered on treatment options for early disease management in a genetically defined population.
- Oral therapy
- APOE4 genotype
- Early Alzheimer’s treatment
The clinical program reflects a medical focus on neurodegenerative disorders and genotype-linked disease subsets.
